SL Therapeutics, Inc.

A258540

KR7258540004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 22/05/2024 BST			5-day change	1st Jan Change
730 ^KRW	0.00%		-9.77%	+23.94%

2022	StemLab Inc. announced that it has received KRW 1.5000006 billion in funding	CI
2022	StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding	CI

StemLab Inc. announced that it has received KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd.

October 26, 2020

On October 27, 2020, StemLab Inc. (XKON:A258540) closed the transaction. The company has received KRW 1,000,000,000 from series 4 bonds.

Latest news about SL Therapeutics, Inc.

StemLab Inc. announced that it has received KRW 1.5000006 billion in funding	13/10/22	CI
StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding	27/07/22	CI
StemLab Inc. announced that it has received KRW 4 billion in funding	03/03/21	CI
StemLab Inc. announced that it expects to receive KRW 4 billion in funding	23/02/21	CI
StemLab Inc. announced that it has received KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd.	26/10/20	CI
StemLab Inc. announced that it expects to receive KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd. and another investor	20/06/19	CI
StemLab Inc. announced that it has received KRW 1.5 billion in funding	28/03/19	CI
StemLab Inc. announced that it expects to receive KRW 1.5 billion in funding	13/03/19	CI

SL Therapeutics Inc, formerly Stem Lab Inc, is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company is principally engaged in the development, research, manufacture and sale of biopharmaceuticals such as stem cell culture mediums, stem cell treatment as well as others.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
SL THERAPEUTICS, INC.	+23.94%	2.79M
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.71%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.41%	14.52B
INCYTE CORPORATION	-7.99%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals

SL Therapeutics, Inc.

Equities

A258540

KR7258540004

Pharmaceuticals

StemLab Inc. announced that it has received KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd.

Latest news about SL Therapeutics, Inc.

Chart SL Therapeutics, Inc.

Company Profile

Sector Biopharmaceuticals